Cite
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients.
MLA
Guttman, Yassky, Emma, et al. “Phase 2a Randomized Clinical Trial of Dupilumab (Anti‐IL‐4Rα) for Alopecia Areata Patients.” Allergy, vol. 77, no. 3, Mar. 2022, pp. 897–906. EBSCOhost, https://doi.org/10.1111/all.15071.
APA
Guttman, Y. E., Renert, Y. Y., Bares, J., Chima, M., Hawkes, J. E., Gilleaudeau, P., Sullivan, W. M., Singer, G. K., Garcet, S., Pavel, A. B., Lebwohl, M. G., & Krueger, J. G. (2022). Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients. Allergy, 77(3), 897–906. https://doi.org/10.1111/all.15071
Chicago
Guttman, Yassky, Emma, Yuval, Yael Renert, Jennifer Bares, Margot Chima, Jason E. Hawkes, Patricia Gilleaudeau, Whalen, Mary Sullivan, et al. 2022. “Phase 2a Randomized Clinical Trial of Dupilumab (Anti‐IL‐4Rα) for Alopecia Areata Patients.” Allergy 77 (3): 897–906. doi:10.1111/all.15071.